Shalini Sharp
2019 - Ultragenyx Pharmaceutical
In 2019, Shalini Sharp earned a total compensation of $2.6M as Chief Financial Officer and Executive Vice President at Ultragenyx Pharmaceutical, a 25% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $218,178 |
|---|---|
| Option Awards | $923,758 |
| Salary | $484,548 |
| Stock Awards | $945,700 |
| Other | $33,337 |
| Total | $2,605,521 |
Sharp received $945.7K in stock awards, accounting for 36% of the total pay in 2019.
Sharp also received $218.2K in non-equity incentive plan, $923.8K in option awards, $484.5K in salary and $33.3K in other compensation.
Rankings
In 2019, Shalini Sharp's compensation ranked 4,684th out of 13,971 executives tracked by ExecPay. In other words, Sharp earned more than 66.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,684 out of 13,971 | 67th |
Division Manufacturing | 1,749 out of 5,701 | 69th |
Major group Chemicals And Allied Products | 611 out of 2,200 | 72nd |
Industry group Drugs | 515 out of 1,886 | 73rd |
Industry Pharmaceutical Preparations | 388 out of 1,398 | 72nd |
Source: SEC filing on April 29, 2020.
Sharp's colleagues
We found four more compensation records of executives who worked with Shalini Sharp at Ultragenyx Pharmaceutical in 2019.
2019
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
2019
John Pinion
Ultragenyx Pharmaceutical
Chief Quality Officer and Executive Vice President, Translational Sciences
2019
Camille Bedrosian
Ultragenyx Pharmaceutical
Chief Medical Officer
2019
Thomas Kassberg
Ultragenyx Pharmaceutical